Idorsia and viatris successfully close the transaction for the global research and development collaboration

Ad hoc announcement pursuant to art. 53 lr allschwil, switzerland – march 18, 2024 idorsia ltd (six: idia) today announced that it has successfully closed the transaction with viatris inc. (nasdaq: vtrs), a global healthcare company, for the global research and development collaboration, focused on the development and commercialization of two innovative compounds, selatogrel and cenerimod, discovered by idorsia.
VTRS Ratings Summary
VTRS Quant Ranking